sars-cov-2 infection; sars-cov-2 infection; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency. the reporter is the patient. a 35 year-old female patient received bnt162b2 (bnt162b2), administration date 28may2021 (batch/lot number: unknown) as dose 1, single for covid-19 immunisation; covid-19 vaccine (covid-19 vaccine) (batch/lot number: unknown) as dose 2, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: drug ineffective (medically significant), covid-19 (medically significant) all with onset 02jan2022, outcome "recovered" (26jan2022) and all described as "sars-cov-2 infection". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. additional information: patient last menstrual period date: 01feb2022. patient was not enrolled in clinical trial. the patient had covid in january. adverse reaction did not occur as a result of an exposure during pregnancy. case reported as serious by health authority (other medically important condition). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200204808 same reporter/patient/vaccine, different dose/events

test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test

na

na